ArticleDiscover oncology2025
MASP1 in stomach adenocarcinoma: linking diagnosis, prognosis, and tumor immunity.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine learning-based determination of sex-related bladder cancer biomarkers.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study explored the role of Mannose-Binding Lectin-Associated Serine Protease 1 (MASP1) in the diagnosis, prognosis, and immune landscape of stomach adenocarcinoma (STAD), with the aim of providing a molecular foundation for developing early, non-invasive diagnostic tools and advancing immunotherapeutic strategies.
methodsWe analyzed STAD messenger RNA (mRNA) data from The Cancer Genome Atlas (TCGA), immune-related gene data from the ImmPort database, and complement system-related genes from previous studies. Differentially expressed mRNAs (DEmRNAs) relevant to prognosis, immunity, and the complement system were identified using the "limma" and "survival" packages, alongside a Venn diagram. We confirmed MASP1 expression through analysis of external databases, as well as performing quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting (WB) on the normal gastric cell line and various gastric cancer cell lines. The diagnostic performance of MASP1 was evaluated through Receiver Operating Characteristic (ROC) curve analysis using the "pROC" package. Chi-square tests were conducted to examine the association between MASP1 expression and clinicopathological factors. Univariate and multivariate Cox regression analyses were performed to quantify the survival impact of MASP1 expression. Enrichment analyses were conducted to elucidate the functions and pathways associated with MASP1. The relationship between MASP1 expression and tumor immune infiltration was analyzed using single-sample Gene Set Enrichment Analysis (ssGSEA), Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT), Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE), and Spearman correlation methods.
resultOur findings demonstrated that MASP1 is a significant biomarker associated with immune response and prognosis in STAD patients. Elevated MASP1 expression was correlated with poorer clinical outcomes, with ROC curve analysis revealing an Area Under the Curve (AUC) of 0.725 for MASP1. Additionally, MASP1 was identified as an independent prognostic marker for overall survival (OS) in STAD patients. The expression of MASP1 in STAD was predominantly linked to DNA damage repair and cell cycle regulation mechanisms. Furthermore, MASP1 expression showed a significant association with tumor-infiltrating immune cells and immune-related molecules.
conclusionThis study highlights the significant correlation between MASP1 and the immunological landscape of STAD. MASP1 has the potential to serve as a diagnostic and prognostic marker and could be a promising therapeutic target for immunotherapy in STAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.